Corcept Therapeutics Incorporated (CORT)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Corcept Therapeutics Incorporated keeps $37 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Corcept Therapeutics’ revenue topped consensus in the third fiscal quarter of 2026, with results reported November 3, 2026, as revenue rose 64% to about $340.5 million, up from $207.6 million a year ago, and came in at $340.5 million versus a $336.4 million estimate (+1.2%, topped). The quarter’s sales were driven by Korlym, the company’s cortisol modulation product in the U.S. commercial business. Profitability stayed high, with gross profit of roughly $335.9 million translating to a gross margin of ~99%, and the company generated operating cash flow of about $142.9 million. On the forward view, next-period consensus calls for EPS of $1.13 on revenue of $388.7 million.
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated (NASDAQ: CORT) is a U.S. pharmaceutical company focused on cortisol modulation. Its business today centers on Korlym, an oral medication taken once daily, and it generated $761.4 million of revenue in FY2025 from operations in the healthcare sector.
Today's Snapshot
The day ended with CORT 3.2% lower at 67.79, in line with a weaker sector. Volume was about two-thirds of its usual level.
Trading Volume
Below 10d avg (1.2M)
744.8K
vs S&P 500 Today
Underperforming Market
-2.99%
Updated: November 18, 2026 at 21:28 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$73.36 - $94.24Sell
- RSI (14)23.67Buy
- Stochastic %K (14, 3, 3)6.17Buy
- MACD Level (12, 26)-9.69Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.